|Company Name:||Creative Peptides
|Tel:||+1 (866) 588-6325|
|Synonyms:||Liraglutide;Glycine, L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(1-oxohexadecyl)-L-gamma-glutamyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-;Liraglutida;Liraglutida [inn-spanish];Liraglutide [usan:inn];Liraglutidum;Liraglutidum [inn-latin];N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glp-1-(7-37)-peptide|
|Mol File:||Mol File|
|Liraglutide Chemical Properties|
|Liraglutide Usage And Synthesis|
|Medicine for treating type 2 diabetes mellitus||As a new long-acting GLP-1 analogues liraglutide, GLP-1 has 97% sequence homology, human GLP-1 can bind to and activate GLP-1 receptor. GLP-1 receptor as the target of natural GLP-1, GLP-1 is a kind of endogenous incretin hormone, can promote islet βcell proliferation and differentiation, protective and improved the function of islet β cells. And liraglutide is simple and convenient, once a day can provide 24 h blood glucose control, and low risk of hypoglycemia, is expected to become a new drug for treatment of type 2 diabetes.|
Liraglutide is the first and currently the only GLP-1 (pancreatic glucagon like peptide - 1) analogues, which has been widely used in Europe, the United States and Japan. Pancreatic glucagon like peptide-1 is a kind of incretin insulin when oral intake of nutrients, pancreatic glucagon like peptide - 1 can promote insulin secret, but human GLP-1 can be dipeptide based peptidase 4 (DPP-4) rapidly degraded. Liraglutide is GLP-1 receptor full agonist, 97% of the amino acid sequence is the same molecule of human GLP-1. People said that there are two differences between two molecules. First of all, C16 fatty acids in the 26th by glutamate connection to lysine acid. Secondly, in the 34 lysine acid is replaced by arginine, to ensure that C16 side chain can only be combined in the 26. Fatty acid side chains can liraglutide in night's blood and albumin reversible combination, so that the action time of liraglutide extended and enhanced degradation of the DPP-4 enzyme to resist and fatty acid side chains can also enable liraglutide molecular selfing in injection site into heptamers, thus delaying the subcutaneous attract, the function of the time for up to 24 hours, daily injections of a and in injection for any length of time has nothing to do with meal.
Liraglutide is type 2 diabetes therapy and revolutionized the field of drug , Applicable to use metformin or sulfonylureas maximum tolerated dose still poorly controlled blood sugar after treatment in patients with type 2 diabetes, glucose concentration dependent manner to regulate blood sugar, protect B cells directly, increase insulin secretion and decrease a cell in inappropriate glucagon secretion, by increasing satiety and reducing caloric intake and body weight reduction, lower systolic blood pressure (SBP), earlier used better. Liraglutide peptide with metformin or a sulfonylurea drug combination has a significant effect, less adverse reaction.
The above information is edited by the Chemicalbook Hanya.
|Adverse reaction||Liraglutide treatment process is very low in the incidence of hypoglycemia. Gastrointestinal discomfort is the most common adverse reactions in the liraglutide treatment, slowly increasing the liraglutide dosage can reduce the proportion of dose related nausea. Gastrointestinal discomfort commonly appear at the first week in liraglutide treatment, diarrhea and nausea occur most frequently, most of them are short, slight or tolerable, and are related with liraglutide dose.
|Liraglutide Preparation Products And Raw materials|